Puma Biotechnology | PBYI - Interest Expense On Debt


Puma Biotechnology reported $3.37M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Agios Pharmaceuticals USD 1.18B 4.3B Mar/2026
Alnylam Pharmaceuticals USD 69.29M 60.05M Mar/2026
Amgen USD 657M 4M Mar/2026
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 14.96M 12.18M Mar/2026
Daiichi Sankyo JPY 2.16B 1.33B Dec/2025
Esperion Therapeutics USD 22.64M 585K Dec/2025
Exelixis USD 23.4M 3.9M Sep/2023
Gilead Sciences USD 240M 15M Mar/2026
Glaxosmithkline GBP 192.73M 14.79M Mar/2026
Incyte USD 569K 13K Mar/2026
MacroGenics USD 4.89M 1.55M Mar/2026
Moderna USD 11.49B 36B Mar/2026
Novartis USD 343M 39M Mar/2026
Pfizer USD 671M 40M Mar/2026
PTC Therapeutics USD 2.87B 2.82B Mar/2026
Puma Biotechnology USD 3.37M 11K Jun/2024
Regeneron Pharmaceuticals USD 12.9M 700K Mar/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sangamo BioSciences 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 20.84M 13.28M Dec/2025
Takeda JPY 43.65B 79.98B Mar/2026
TG Therapeutics USD 7.67M 1.13M Mar/2026
Ultragenyx Pharmaceutical USD 21M 2M Mar/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025